Suppliers / ScinoPharm Taiwan

ScinoPharm Taiwan

Taiwan 1789.TW 197 employees Updated 9 July 2026

ScinoPharm Taiwan is an API manufacturer based in Taiwan. It holds 71 active US drug master files. Its most recent recorded inspection, by US FDA, closed on 25 October 2022 as NAI.

71
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 25 October 2022 NAI US FDA
  • 17 May 2019 NAI US FDA
  • 10 February 2017 NAI US FDA
  • 27 March 2015 NAI US FDA
  • 29 March 2012 VAI US FDA
  • 23 October 2008 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Taiwan, Taiwan 3002840477

What they file, and where

Molecule Regulators Docs
Docetaxel SFDA (Saudi Arabia), US FDA 5
Gemcitabine SFDA (Saudi Arabia), US FDA 3
Olaparib SFDA (Saudi Arabia), US FDA 3
Paclitaxel SFDA (Saudi Arabia), US FDA 3
Azacitidine SFDA (Saudi Arabia), US FDA 2
Cladribine SFDA (Saudi Arabia), US FDA 2
Decitabine US FDA 2
Exemestane SFDA (Saudi Arabia), US FDA 2
Galantamine US FDA 2
Irinotecan SFDA (Saudi Arabia), US FDA 2
Show all 30 molecules on file
Letrozole SFDA (Saudi Arabia), US FDA 2
Pemetrexed US FDA 2
Topotecan SFDA (Saudi Arabia), US FDA 2
Abemaciclib US FDA 1
Alectinib US FDA 1
Alpelisib US FDA 1
Anastrozole US FDA 1
Apixaban US FDA 1
Apremilast US FDA 1
Atazanavir US FDA 1
Benazepril US FDA 1
Bimatoprost US FDA 1
Bivalirudin US FDA 1
Bortezomib US FDA 1
Brexpiprazole US FDA 1
Capecitabine US FDA 1
Cedazuridine US FDA 1
Celecoxib US FDA 1
Clofarabine US FDA 1
Dantrolene US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 3 None

Comparing suppliers?

Choose your molecules and target markets. ScinoPharm Taiwan comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 4 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 25 October 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability